Skip to main content
SpringerLink
Log in

Adverse Haematological Effects of Ticlopidine

Prevention, Recognition and Management

  • Review Article
  • Drug Experience
  • Published:
Drug Safety Aims and scope Submit manuscript

Abstract

Ticlopidine is an antiplatelet agent that is used to reduce the occurrence of atherothrombotic arterial events. There have been major multicentre placebo-controlled trials evaluating its use in stroke, peripheral arterial disease and unstable angina. In rare cases, adverse haematological effects have been seen with ticlopidine.

Ticlopidine has been associated with neutropenia in some of the major trials and in subsequent case reports it has been associated with aplastic anaemia, thrombocytopenia and thrombotic thrombocytopenic purpura, which have been fatal in some instances. Ticlopidine should be used only in patients with an established indication for its use. Patients should be educated about the potential adverse effects and complications associated with ticlopidine, including possible death. Finally, there should be careful attention to haematological monitoring to screen for and promptly detect any adverse effects.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Gent M, Blakeley JA, Easton JD, and the CATS Group. The Canadian-American Ticlopidine Study (CATS) in thromboembolic stroke. Lancet 1989; I: 1215–20

    Article  Google Scholar 

  2. Hass WK, Easton JD, Adams HP, et al. for the Ticlopidine Aspirin Study Group. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high risk patients. N Engl J Med 1989; 321: 501–7

    Article  PubMed  CAS  Google Scholar 

  3. Janzon L, Bergqvist D, Boberg J, et al. Prevention of myocardial infarction and stroke in patients with intermittent claudication; effects of ticlopidine. Results from STIMS, the Swedish Ticlopidine Multicentre Study. J Intern Med 1990; 227: 301–8

    Article  PubMed  CAS  Google Scholar 

  4. Balsano F, Rizzon P, Violi F, et al. and the STAI group. Antiplatelet treatment with ticlopidine in unstable angina: a controlled multicenter clinical trial. Circulation 1990; 82: 17–26

    Article  PubMed  CAS  Google Scholar 

  5. Schomig A, Neumann F-J, Kastrati A, et al. A randomized comparison of antiplatelet and anticoagulation therapy after the placement of coronary-artery-stents. N Engl J Med 1996; 334: 1084–9

    Article  PubMed  CAS  Google Scholar 

  6. Antiplatelet Trialists’ Collaboration. Collaborative overview of randomised trials of antiplatelet therapy. I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994; 308: 81–106

    Article  Google Scholar 

  7. Becquemin J-P, for the Etude de la Ticlopidine Aprés Pontage Femero-Poplité and the Association Universitaire de Recherche en Chirugie. Effect of ticlopidine on long-term patency of saphenous-vein bypass grafts in the legs. N Engl J Med 1997; 337: 1726–31

    Article  PubMed  CAS  Google Scholar 

  8. Saltiel E, Ward A: Ticlopidine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in platelet-dependent disease states. Drugs 1987; 34: 222–62

    Article  PubMed  CAS  Google Scholar 

  9. Stein B, Fuster V, Israel DH, et al. Platelet inhibitor agents in cardiovascular disease: an update. J Am Coll Cardiol 1989; 813-36

  10. Defreyn G, Bernat A, Delebassee D, et al. Pharmacology of ticlopidine: a review. Semin Thromb Hem 1989; 15: 159–66

    Article  CAS  Google Scholar 

  11. Shah J, Teitelbaum P, Moloby B, et al. Single and multiple dose pharmacokinetics of ticlopidine in young and elderly subjects. Br J Clin Pharmacol 1991; 32: 761–4

    PubMed  CAS  Google Scholar 

  12. Barnett HJM, Eliasziw M, Meldrum HE. Prevention of ischemic stroke [letter]. N Engl J Med 1995; 333: 460

    Google Scholar 

  13. Wysowksi DK, Bacsanyi J. Blood dyscrasias and hematologic reactions in ticlopidine users [letter]. JAMA 1996; 276: 952

    Article  PubMed  CAS  Google Scholar 

  14. National Disease and Therapeutic Index. Plymouth Meeting PA: IMS America, 1992–1995

  15. Quaglino D, Venturoni L, Cretara G, et al. Reversible bone marrow suppression primarily involving granulopoiesis following the use of ticlopidine. Haematologica 1982; 67: 940–1

    PubMed  CAS  Google Scholar 

  16. Resegotti L, Pistone MA, Testa D, et al. Bone marrow culture in patients receiving ticlopidine treatment. Nouv Rev Fr Hematol 1985; 27: 19–22

    PubMed  CAS  Google Scholar 

  17. Abou-Khalil WH, Lim LO, Yunnis AA, et al. Effects of ticlopidine, a new platelet antiaggregating agent, and its analogues on mitochondrial metabolism, oxidative phosphorylation, protein synthesis and DNA polymerase activity. Biochem Pharmacol 1984; 33: 3893–8

    Article  PubMed  CAS  Google Scholar 

  18. Haynes RB, Sandler RS, Larson EB, et al. A critical appraisal of ticlopidine, a new antiplatelet agent. Effectiveness and clinical indications for prophylaxis of atherosclerotic events. Arch Intern Med 1992; 152: 1376–80

    Article  PubMed  CAS  Google Scholar 

  19. Haushofer A, Halbmayer WM, Prachar H. Neutropenia with ticlopidine plus aspirin. Lancet 1997; 349: 474–5

    Article  PubMed  CAS  Google Scholar 

  20. Ono K, Kurohara K, Yoshihara M, et al. Agranulocytosis caused by ticlopidine and its mechanism. Am J Hematology 1991; 37: 239–42

    Article  CAS  Google Scholar 

  21. Elias M, Reichman N, Flatau E. Bone marrow aplasia associated with ticlopidine therapy [letter]. Am J Hematol 1993; 44: 289–91

    Article  PubMed  CAS  Google Scholar 

  22. Farver DK, Hansen LA. Delayed neutropenia with ticlopidine. Ann Pharmacother 1994; 28: 1344–6

    PubMed  CAS  Google Scholar 

  23. Gelatko SM, Melbourne KM, Mikolich DJ. Pseudomonas bacteremia precipitated by ticlopidine-induced neutropenia. Ann Pharmacother 1996; 30: 246–8

    Google Scholar 

  24. Johanning RJ, Tschida SJ. Pseudomonas bacteremia secondary to ticlopidine-induced agranulocytosis [letter]. Ann Pharmacother 1996; 30: 1201

    PubMed  CAS  Google Scholar 

  25. Carlson JA, Maesner JE. Fatal neutropenia and thrombocytopenia associated with ticlopidine. Ann Pharmacother 1994; 28: 1236–7

    PubMed  CAS  Google Scholar 

  26. Ruiz-Irastorza G, Alonso JJ, Iglesias JJ, et al. Granulocyte colony-stimulating factor for neutropenia secondary to ticlopidine. Acta Haematol 1994; 91: 106–7

    Article  PubMed  CAS  Google Scholar 

  27. Gamier G, Taillan B, Pesce A, et al. Ticlopidine and severe aplastic anemia [letter]. Br J Haematology 1992; 81: 459–60

    Article  Google Scholar 

  28. Troussard X, Mayo P, Mosquet B, et al. Ticlopidine and severe aplastic anemia [letter]. Br J Haematol 1992; 82: 779–80

    Article  PubMed  CAS  Google Scholar 

  29. Khelif A, Assouline D, French M, et al. Ticlopidine and aplastic anaemia [letter]. Br J Haematol 1993; 83: 678–81

    Article  PubMed  CAS  Google Scholar 

  30. Martin-Nunez G, Fdex-Soria RR, Sanchez-Gil F, et al. Aplastic anemia and ticlopidine [letter]. Br J Haematol 1991; 85: 633–40

    Article  Google Scholar 

  31. Lesesve J-F, Callat M-P, Lenormand B, et al. Hematological toxicity of ticlopidine [letter]. Am JHematol 1994; 47: 149–50

    Article  CAS  Google Scholar 

  32. Mallet L, Mallet J. Ticlopidine and fatal aplastic anemia in an elderly woman. Ann Pharmacother 1994; 28: 1169–71

    PubMed  CAS  Google Scholar 

  33. Rodriguez JN, Fernandez-Jurado A, Dieguez JC, et al. Ticlopidine and severe aplastic anemia [letter]. Am J Hematol 1994; 47: 332

    Article  PubMed  CAS  Google Scholar 

  34. Arribalzaga K, Garcia-Suärez, Lopez-Rubio M, et al. Sustained granulocyte recovery after G-CSF in a patient with ticlopidine-induced severe aplastic anemia [letter]. Am J Hematol 1995; 50: 313–20

    Article  PubMed  CAS  Google Scholar 

  35. Dunn P. Aplastic anemia with ticlopidine therapy in two Chinese patients [letter]. Ann Pharmacother 1996; 30: 547

    PubMed  CAS  Google Scholar 

  36. Shapiro CM, Walk D. Aplastic anemia associated with ticlopidine [letter]. Neurology 1996; 47: 300

    Article  PubMed  CAS  Google Scholar 

  37. Yunis AA, Arimura GK, Lo L. Comparative effects of ticlopidine and analogues on in vitro myeloid colony (CGU-GM) growth. Agents and Actions Supplements, Ticlopidine: Quo Vadis? 1984; 15: 136–47

    CAS  Google Scholar 

  38. Takishita S, Kawazoe N, Yoshida T, et al. Ticlopidine and thrombocytopenia [letter]. N Engl J Med 1990; 323: 1487

    Article  PubMed  CAS  Google Scholar 

  39. Capra R, Marciano N, Fieni F, et al. Cerebral hemorrhage and thrombotic thrombocytopenic purpura during ticlopidine treatment: case report. Acta Neurol Belg 1992; 92: 83–7

    PubMed  CAS  Google Scholar 

  40. Ariyoshi K, Shinohara K, Ruirong X. Thrombotic thrombocytopenic purpura caused by ticlopidine, successfully treated by plasmapheresis. Am J Hematol 1997; 54: 175–6

    Article  PubMed  CAS  Google Scholar 

  41. Falezza G, Girelli D, Olivieri O, et al. Thrombotic thrombocytopenic purpura developed during ticlopidine therapy [letter]. Haematologica 1992; 77: 525

    PubMed  CAS  Google Scholar 

  42. Kovacs MJ, Soong PY, Chin-Yee IH. Thrombotic thrombocytopenic purpura associated with ticlopidine. Ann Pharmacother 1993; 27: 1060–1

    PubMed  CAS  Google Scholar 

  43. Page Y, Tardy B, Zeni F, et al. Thrombotic thrombocytopenic purpura related to ticlopidine. Lancet 1991; 337: 774–6

    Article  PubMed  CAS  Google Scholar 

  44. Ellie E, Durrieu C, Besse P, et al. Thrombotic thrombocytopenic purpura associated with ticlopidine. Stroke 1992; 23: 922–3

    Article  PubMed  CAS  Google Scholar 

  45. Piscotto P. Treatment of thrombocytopenic purpura: evaluation of plasma exchange and review of the literature. Vox Sang 1983; 45: 185–96

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neurology, Indiana University School of Medicine, Emerson Hall 125, 545 Barnhill Drive, Indianapolis, Indiana, IN 46202-5124, USA

    Betsy B. Love &  José Biller

  2. Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Ontario, Canada

    Michael Gent

  3. Hamilton Civic Hospitals Research Centre, Henderson General Division, Clinical Trials Methodology Group, Hamilton, Ontario, Canada

    Michael Gent

Authors
  1. Betsy B. Love
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. José Biller
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Michael Gent
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Love, B.B., Biller, J. & Gent, M. Adverse Haematological Effects of Ticlopidine. Drug-Safety 19, 89–98 (1998). https://doi.org/10.2165/00002018-199819020-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002018-199819020-00002

Keywords

Search

Navigation